A
RCUS
Arcus Bioscience
23.43
-0.44-1.84%After Hours: 23.43 0.00 0.00%16:10 05/22 EDT
OPEN/PREV CLOSE23.84/23.87
TODAY RANGE23.42-24.34
VOL516.53K
MARKET CAP2.95B
52 WEEK RANGE7.91-28.72
AVG VOL (3M)1.20M
% TURNOVER0.41%
TURNOVER--
P/E (TTM)-7.3614
% RANGE3.85%
EPS(TTM)-3.1828
P/E(FORWARD)-6.4545
P/B5.61
BVPS4.175
DIVIDEND--
P/S11.89
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.08B
SHARES OUTSTANDING125.77M
NEXT EARNINGS08/04-08/10
FREE FLOAT88.80M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·5d ago
Arcus Biosciences Coverage Assumed by Truist Securities at Buy
TipRanks·5d ago
Arcus Biosciences assumed with a Buy at Truist
Simply Wall St·05/16 13:59
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21%
Dow Jones·05/11 17:16
Arcus Biosciences Is Maintained at Equal-Weight by Morgan Stanley
Simply Wall St·05/09 21:31
Assessing Arcus Biosciences (RCUS) Valuation After Trial Discontinuations Collaboration Setback And Weak Q1 Results
Simply Wall St·05/08 13:58
Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Dow Jones·05/07 16:31
Arcus Biosciences Is Maintained at Buy by Goldman Sachs
Dow Jones·05/07 16:31
Arcus Biosciences Price Target Raised to $34.00/Share From $30.00 by Goldman Sachs
Benzinga·05/07 16:21
Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
Simply Wall St·05/07 12:36
Arcus Biosciences Q1 Loss Of US$128 Million Reinforces Bearish Profitability Concerns
TipRanks·05/07 11:09
Goldman Sachs Remains a Buy on Arcus Biosciences (RCUS)
Simply Wall St·05/06 10:23
Is It Too Late To Consider Arcus Biosciences (RCUS) After Its 221% One Year Surge?